Literature DB >> 28101687

Noncoding RNA for Cancer Gene Therapy.

Xiaomin Zhong1,2, Dongmei Zhang3,4, Minmin Xiong5, Lin Zhang3.   

Abstract

Gene therapy is a prospective strategy to modulate gene expression level in specific cells to treat human inherited diseases, cancers, and acquired disorders. A subset of noncoding RNAs, microRNAs (miRNAs) and small interference RNAs (siRNAs), compose an important class of widely used effectors for gene therapy, especially in cancer treatment. Functioning through the RNA interference (RNAi) mechanism, miRNA and siRNA show potent ability in silencing oncogenic factors for cancer gene therapy. For a better understanding of this field, we reviewed the mechanism and biological function, the principles of design and synthesis, and the delivery strategies of noncoding RNAs with clinical potentials in cancer gene therapy.

Entities:  

Keywords:  Cancer; Gene therapy; MicroRNA; Noncoding RNA; RNA interference; Small interference RNA

Mesh:

Substances:

Year:  2016        PMID: 28101687      PMCID: PMC5663289          DOI: 10.1007/978-3-319-42934-2_4

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  50 in total

1.  A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA.

Authors:  G Hutvágner; J McLachlan; A E Pasquinelli; E Bálint; T Tuschl; P D Zamore
Journal:  Science       Date:  2001-07-12       Impact factor: 47.728

2.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

3.  Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors:  Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

4.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

Authors:  Masato Nishimura; Eun-Jung Jung; Maitri Y Shah; Chunhua Lu; Riccardo Spizzo; Masayoshi Shimizu; Hee Dong Han; Cristina Ivan; Simona Rossi; Xinna Zhang; Milena S Nicoloso; Sherry Y Wu; Maria Ines Almeida; Justin Bottsford-Miller; Chad V Pecot; Behrouz Zand; Koji Matsuo; Mian M Shahzad; Nicholas B Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; George A Calin
Journal:  Cancer Discov       Date:  2013-09-03       Impact factor: 39.397

5.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

6.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

7.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer.

Authors:  Aurora Esquela-Kerscher; Phong Trang; Jason F Wiggins; Lubna Patrawala; Angie Cheng; Lance Ford; Joanne B Weidhaas; David Brown; Andreas G Bader; Frank J Slack
Journal:  Cell Cycle       Date:  2008-03-03       Impact factor: 4.534

8.  Activation of the interferon system by short-interfering RNAs.

Authors:  Carol A Sledz; Michelle Holko; Michael J de Veer; Robert H Silverman; Bryan R G Williams
Journal:  Nat Cell Biol       Date:  2003-08-24       Impact factor: 28.824

9.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

10.  Suppression of non-small cell lung tumor development by the let-7 microRNA family.

Authors:  Madhu S Kumar; Stefan J Erkeland; Ryan E Pester; Cindy Y Chen; Margaret S Ebert; Phillip A Sharp; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

View more
  3 in total

1.  Coordinated targeting of MMP-2/MMP-9 by miR-296-3p/FOXCUT exerts tumor-suppressing effects in choroidal malignant melanoma.

Authors:  Xinhe Wang; Yuedong Hu; Jianyi Cui; Yun Zhou; Lei Chen
Journal:  Mol Cell Biochem       Date:  2017-12-19       Impact factor: 3.396

Review 2.  Targeting Akt-associated microRNAs for cancer therapeutics.

Authors:  Mir S Adil; Daulat Khulood; Payaningal R Somanath
Journal:  Biochem Pharmacol       Date:  2020-12-24       Impact factor: 6.100

Review 3.  Adeno-associated virus (AAV)-based gene therapy for glioblastoma.

Authors:  Xin Xu; Wenli Chen; Wenjun Zhu; Jing Chen; Bin Ma; Jianxia Ding; Zaichuan Wang; Yifei Li; Yeming Wang; Xiaochun Zhang
Journal:  Cancer Cell Int       Date:  2021-01-26       Impact factor: 5.722

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.